A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer’s disease

References

• Dua T, Nichols P, Setoya Y (2012). Dementia: a public health priority. [cited 2017 Oct 10]. Available from: http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf?ua=1.
   Google Scholar
• Wong S, Gilmour H, Ramage-Morin P (2017). Alzheimer’s disease and other dementias in Canada. [cited 2017 Oct 8]. Available from: http://www.statcan.gc.ca/pub/82-003-x/2016005/article/14613-eng.htm.
   Google Scholar
• Copstead L-EC, Banasik JL. Pathophysiology. 5th ed. ed. St. Louis: Saunders; 2013.
   Google Scholar
• Pouryamout L, Dams J, Wasem J, et al. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs. 2012;72:789–802.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Disease International. World Alzheimer report 2015. [cited 2018 May 7]. Available from: https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf.
   Google Scholar
• FDA approved treatments for Alzheimer’s. [cited 2018 May 7]. Available from: https://www.alz.org/national/documents/topicsheet_treatments.pdf.
   Google Scholar
• Deardorff W, Grossberg G. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug Des Devel Therapy. 2016;10:3267–3279.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K. et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• Alzheimer Society of Canada. Treatment: drug treatments. Toronto: Alzheimer Society of Canada. [cited 2017 Nov 14]. Available from: www.alzheimer.ca/english/treatment/treatments-intro.htm.
   Google Scholar
• Ontario drug benefit formulary/comparative drug index. 2018. [cited 2018 Apr 30]; [ cited 2018 May 7]. Available from: http://www.health.gov.on.ca.;http://www.health.gov.on.ca/en/pro/programs/drugs/formulary42/summary_edition42_201402.pdf.
   Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
   PubMed Web of Science ®Google Scholar
• Inflation calculator. [cited 2018 May 1]. Available from: http://www.fxtop.com.
   Google Scholar
• Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240–245.
   PubMed Web of Science ®Google Scholar
• Getsios D, Blume S, Ishak K, et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimerʼs disease. PharmacoEconomics. 2010;28:411–427.
   PubMed Web of Science ®Google Scholar
• Fagnani F, Lafuma A, Pechevis M, et al. Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications. Dement Geriatr Cogn Dis. 2004;17:5–13.
   PubMed Web of Science ®Google Scholar
• Fuh J, Wang S. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer’s disease in Taiwan. Int J Geriatr Psychiatry. 2007;23:73–78.
   Web of Science ®Google Scholar
• Hartz S, Getsios D, Tao S, et al. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer’s disease in Germany using discrete event simulation. BMC Neurology. 2012;12:2.
   PubMed Web of Science ®Google Scholar
• Jonsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther. 1999;21:1230–1240.
   PubMed Web of Science ®Google Scholar
• Kasuya M, Meguro K. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer’s disease as shown by the Markov model. Arch Gerontol Geriatr. 2010;50:295–299.
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Hart W, García-Pérez L, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. J Alzheimers Dis. 2009;16:399–407.
   PubMed Web of Science ®Google Scholar
• Neumann P, Hermann R, Kuntz K, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology. 1999;52:1138.
   PubMed Web of Science ®Google Scholar
• O’Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc. 1999;47:570–578.
   PubMed Web of Science ®Google Scholar
• Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer’s disease: a Markov-cycle evaluation of five years therapy using donepezil. Int J Geriatr Psychiatry. 1998;13:445–453.
   PubMed Web of Science ®Google Scholar
• Teipel S, Ewers M, Reisig V, et al. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2007;257:330–336.
   PubMed Web of Science ®Google Scholar
• Fenn P, Gray A. Estimating long term cost savings from treatment of Alzheimer’s disease. PharmacoEconomics. 1999;16:165–174.
   PubMed Web of Science ®Google Scholar
• Hauber ABA, Gnanasakthy A, Mauskopf J. Savings in the cost of caring for patients with Alzheimer’s disease in Canada: an analysis of treatment with rivastigmine. Clin Ther. 2000;22:439–451.
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro J, Caro G, et al. Assessment of health economics in Alzheimer’s disease (AHEAD): galantamine treatment in Canada. Neurology. 2001;57:972–978.
   PubMed Web of Science ®Google Scholar
• Nagy B, Brennan A, Brandtmüller Á, et al. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry. 2010;26:483–494.
   PubMed Web of Science ®Google Scholar
• Caro J, Salas M, Ward A, et al. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer’s disease in the health care systems of different countries. Drugs Aging. 2004;21:677–686.
   PubMed Web of Science ®Google Scholar
• Caro J, Salas M, Ward A, et al. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in the Netherlands. Dement Geriatr Cogn Disord. 2002;14:84–89.
   PubMed Web of Science ®Google Scholar
• Marin D, Amaya K, Casciano R, et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer’s disease. Int Psychogeriatr. 2003;15:385–398.
   PubMed Web of Science ®Google Scholar
• Migliaccio-Walle K, Getsios D, Caro J, et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer’s disease in the United States. Clin Ther. 2003;25:1806–1825.
   PubMed Web of Science ®Google Scholar
• Ward A, Caro J, Getsios D, et al. Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry. 2003;18:740–747.
   PubMed Web of Science ®Google Scholar
• Green C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. PharmacoEconomics. 2005;23:1271–1282.
   PubMed Web of Science ®Google Scholar
• Caro J, Getsios D, Migliaccio-Walle K, et al. Rational choice of cholinesterase inhibitor for the treatment of Alzheimer’s disease in Canada: a comparative economic analysis. BMC Geriatrics. 2003;3:6.
   PubMedGoogle Scholar
• Antonanzas F, Rive B, Badenas J, et al. Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain. Eur J Health Econ. 2006;7:137–144.
   PubMedGoogle Scholar
• Francois C, Sintonen H, Sulkava R, et al. Cost effectiveness of memantine in moderately severe to severe Alzheimer’s disease. Clin Drug Invest. 2004;24:373–384.
   PubMed Web of Science ®Google Scholar
• Gagnon M, Rive B, Hux M, et al. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52:519–526.
   PubMed Web of Science ®Google Scholar
• Hoogveldt B, Severens J, Maman K, et al. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands. Neuropsychiatr Dis Treat. 2011;7:313–317.
   PubMed Web of Science ®Google Scholar
• Jones R, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease. Drugs Aging. 2004;21:607–620.
   PubMed Web of Science ®Google Scholar
• Jönsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer’s disease in Sweden. Am J Geriatr Pharmacother. 2005;3:77–86.
   PubMedGoogle Scholar
• Wimo A. Pharmacoeconomic aspects of memantine (Ebixa®) in the treatment of Alzheimer’s disease. Exp Rev Pharmacoecon Outcomes Res. 2003;3:675–680.
   PubMedGoogle Scholar
• Lachaine J, Beauchemin C, Legault M, et al. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatry. 2011;56:596–604.
   PubMed Web of Science ®Google Scholar
• Pfeil A, Kressig R, Szucs T. Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss Med Wkly. 2012;142:w13676.
   PubMed Web of Science ®Google Scholar
• Saint-Laurent Thibault C, Özer Stillman I, Chen S, et al. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US. J Med Econ. 2015;18:930–943.
   PubMed Web of Science ®Google Scholar
• Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ. 2013;15:791–800.
   PubMed Web of Science ®Google Scholar
• Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Cur Med Res Opin. 2007;23:1187–1197.
   PubMed Web of Science ®Google Scholar
• Rive B, Grishchenko M, Guilhaume-Goulant C, et al. Cost effectiveness of memantine in Alzheimer’s disease in the UK. J Med Econ. 2010;13:371–380.
   PubMedGoogle Scholar
• Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004;63:644–650.
   PubMed Web of Science ®Google Scholar
• Suh G, Jung H, Lee C, et al. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population: a 52-week prospective study. J Korean Med Sci. 2008;23:10–17.
   PubMed Web of Science ®Google Scholar
• Knapp M, King D, Romeo R, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial). Int J Geriatr Psychiatry. 2016;32:1205–1216.
   PubMed Web of Science ®Google Scholar
• Hughes CP, Berg L, Danziger W, et al. A new clinical scale for the staging of dementia. Brit J Psychiatry. 1982;140:566–572.
   PubMed Web of Science ®Google Scholar
• Mohs K, Rosen W, Davis K. The Alzheimer’s Disease Assessment Scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19:448–450.
   PubMed Web of Science ®Google Scholar
• Lopez O, Becker J, Wahed A, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:600–607.
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
   PubMed Web of Science ®Google Scholar
• Nickel F, Barth J, Kolominsky-Rabas P. Health economic evaluations of non-pharmacological interventions for persons with dementia and their informal caregivers: a systematic review. BMC Geriatrics. 2018;18:69.
   PubMed Web of Science ®Google Scholar
• Oremus M, Xie F, Gaebel K. Development of clinical vignettes to describe Alzheimer’s disease health states: a qualitative study. Plos One. 2016;11:e0162422.
   PubMed Web of Science ®Google Scholar
• Oremus M, Xie F, Pullenayegum E, et al. Can the general public use vignettes to discriminate between Alzheimer’s disease health states? BMC Geriatr. 2016;16:36.
   PubMed Web of Science ®Google Scholar
• Payakachat N, Ali M, Tilford J. Can the EQ-5D detect meaningful change? A systematic review. PharmacoEconomics. 2015;33:1137–1154.
   PubMed Web of Science ®Google Scholar
• Horsman J, Furlong W, Feeny D, et al. Health Utilities Index (Hui®): concepts, measurement properties, and applications. Health Qual Life Outcomes. 2003;1:54.
   PubMedGoogle Scholar
• Oremus M, Tarride JE, Clayton N, et al. Health utility scores in Alzheimer’s disease: differences based on calculation with American and Canadian preference weights. Value Health. 2014;17:77–83.
   PubMed Web of Science ®Google Scholar
• Oremus M, Cosby JL, Wolfson C. A hybrid qualitative method for pretesting questionnaires: the example of a questionnaire to caregivers of Alzheimer disease patients. Res Nurs Health. 2005;28:419–430.
   PubMed Web of Science ®Google Scholar
• Gilstad JR, Finucane TE. Results, rhetoric, and randomized trials: the case of donepezil. J Am Geriatr Soc. 2008;56:1556–1562.
   PubMed Web of Science ®Google Scholar
• NICE reverses Alzheimer’s drug stance. PMLive. [cited 2018 Mar 18]. Available from: http://www.pmlive.com/pharma_news/nice_reverses_alzheimers_drug_stance_239142.
   Google Scholar
• Getsios D, Migliaccio-Walle K, Caro J. NICE cost-effectiveness appraisal of cholinesterase inhibitors. PharmacoEconomics. 2007;25:997–1006.
   PubMed Web of Science ®Google Scholar
• Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease | guidance and guidelines | NICE. [cited 2018 Mar 18]. Available from: https://www.nice.org.uk/guidance/ta217/chapter/1-guidance.
   Google Scholar
• Adarkwah C, van Gils P, Hiligsmann M, et al. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Exp Rev Pharmacoecon Outcomes Res. 2015;16:513–523.
   PubMed Web of Science ®Google Scholar
• Vemer P, Corro Ramos I, Van Voorn G, et al. AdViSHE: A validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2015;34:349–361.
   Web of Science ®Google Scholar